Can upadacitinib cure rheumatoid arthritis?

Upadacitinib is a selective and reversible JAK1 inhibitor developed using molecular engineering technology. It has been approved by the United States for the treatment of rheumatoid arthritis (RA) . Some randomized double-blind controlled clinical studies have confirmed that upadatinib alone or in combination with glucocorticoids can quickly and significantly relieve rheumatoid arthritis. By regulating the biological effects of the tissue factor signaling pathway, it can reduce pain and improve inflammation. After 16 weeks of treatment with 30 mg of upadatinib for 16 weeks, 66% of patients improved the eczema area and the severity index was 90. Even if the patient's symptoms have been relieved, doctors do not recommend suddenly stopping the medication. If the medication is stopped, the condition may worsen again.